Cic edizioni internazionali
Functional Neurology

Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal

Review, 7 - 18
doi: 10.11138/FNeur/2018.33.1.007
Tag this article
Abstract
Full text PDF
Three different type A botulinum neurotoxins (BoNTAs) — onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA) — are currently marketed in Europe to treat several conditions. Differences between BoNTA preparations, which depend on their
specific biotypes and manufacturing processes, lead to clinically relevant pharmacotherapeutic dissimilarities.
All three available products are separately recognized and reviewed in American Academy of Neurology guidelines. The neurotoxin load/100U is likewise different among the different BoNTAs, with the result that the specific potency of the 150kD BoNTA neurotoxin is calculated as 137 units/ng for onabotulinumtoxinA, 154 units/ng for abobotulinumtoxinA, and 227 units/ng for incobotulinumtoxinA. It is important for clinicians to have all three BoNTAs available in order to choose the most suitable preparation for the specific indication in the single patient. Commercially available BoNTAs must be recognized as different from one another, and therefore as non-interchangeable.
The essential experience of the clinician is of the utmost importance in choosing the most appropriate treatment.

Vol. XXXIII (No. 1) 2018 January/March

  1. Mechanical thrombectomy for acute ischemic stroke: the therapeutic window is larger but still “time is brain»
    Zivelonghi C., Tamburin S.
    doi: 10.11138/FNeur/2018.33.1.005
  2. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal
    Ferrari A., Manca M., Tugnoli V., Alberto L.
    doi: 10.11138/FNeur/2018.33.1.007
  3. Multicentre registry of brain-injured patients with disorder of consciousness: rationale and preliminary data
    Pascarella A., Fiorenza S., Masotta O., Tibollo V., Vella D., Nardone A. M., Rossi M., Volanti P., Madonia F., Castronovo G., De Cicco D., Guarnaschelli C., Achilli M.P., Chiapparino C., Angelillo M.T., Tommasi M.A., Pisano F., Grioni G., Vezzadini G., Ferriero G., Salvaderi S., Bellazzi R., Estraneo A.
    doi: 10.11138/FNeur/2018.33.1.019
  4. Apathy in Parkinson’s disease: differences between caregiver’s report and self-evaluation
    Valentino V., Iavarone A., Amboni M., Moschiano F., Picillo M., Petretta V., Cicarelli G.
    doi: 10.11138/FNeur/2018.33.1.031
  5. Management of spasticity with onabotulinumtoxinA: practical guidance based on the italian real-life post-stroke spasticity survey
    Sandrini G., Baricich A., Cisari C., Paolucci S., Smania N., Picelli A.
    doi: 10.11138/FNeur/2018.33.1.037
  6. A role for accelerometry in the differential diagnosis of tremor syndromes
    Bove F., Di Lazzaro G., Mulas D., Cocciolillo F., Di Giuda D., Bentivoglio A.R.
    doi: 10.11138/FNeur/2018.33.1.045
  7. Effectiveness of a digital platform for sharing knowledge on headache management: a two-year experience
    Raieli V., Correnti E., Sandullo A., Romano M., Marchese F., Loiacono C., Brighina F.
    doi: 10.11138/FNeur/2018.33.1.051
  8. If you want to understand what it really means to live with cluster headache, imagine... fostering empathy through European patients’ own stories of their experiences
    Rossi P., Little P., De La Torre E.R., Palmaro A.
    doi: 10.11138/FNeur/2018.33.1.057
Last Viewed articles: la lista degli ultimi x visitati.
  1. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal
    Ferrari A., Manca M., Tugnoli V., Alberto L.
    doi: 10.11138/FNeur/2018.33.1.007
credits